Crossmark

Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors

Published Online: 2022-07-25

Published Print: 2022-12

Authors

Sander, Cindy A.

Rush, Elizabeth A.

Shi, Jian

Arantes, Lidia M. R. B.

Tesi, Raymond J.

Ross, Mark A.

Calderon, Michael J.

Watkins, Simon C.

Kirkwood, John M.

Ferris, Robert L.

Butterfield, Lisa H.

Vujanovic, Lazar https://orcid.org/0000-0003-1729-8619
Funding

Funding for this research was provided by:

NIH (P50 CA121973)

National Institute of Dental and Craniofacial Research (R01 DE031947)
License Information

Text and Data Mining valid from 2022-07-25

Version of Record valid from 2022-07-25
More Information

Article History

Received: 27 April 2022

Accepted: 15 July 2022

First Online: 25 July 2022

Declarations

:

: With the UPMC Hillman Cancer Center (HCC) IRB-based informed consent, tumor biopsies were obtained from non-trial melanoma patients (HCC #96-099), as well as melanoma patients enrolled in the trial that tested safety and efficacy of concurrent vemurafenib and high-dose interferon-α2b (IFN-α2b) therapy (HCC #12-107).

: Not applicable.

: L.V. is a co-inventor of a methodology licensed to INmune Bio, Inc. where DN-TNF can be used to prevent or treat malignancies.

Document is current